Glaucoma Costs In Denmark In Treatment Naive Patients
J. Olsen, G. Berdeaux, J. Skov
Published 2013 · Medicine
Download PDFAnalyze on Scholarcy
Purpose: To describe the costs and providers of glaucoma treatment in Denmark.
This paper references
A (2007): Barbados Eye Studies Group. Nineyear incidence of open-angle glaucoma in the Barbados Eye Studies
MC Leske (2007)
Costs and effectiveness of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the United Kingdom General Practitioner
A Lafuma (2008)
Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study.
F. Topouzis (2008)
Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States.
G. Kobelt-Nguyen (1998)
Trends in ophthalmic surgery in Ireland
V. W. Long (2005)
Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey.
J. Tielsch (1994)
PREVALENCE OF OPEN-ANGLE GLAUCOMA IN CENTRAL SWEDEN: THE TIERP GLAUCOMA SURVEY
Curt Ekstrom (2009)
Costs of treating primary openangle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients
G Kobelt-Nguyen (1998)
Costs and effectiveness of Travatan (travoprost) versus Xalacom (Latanoprost + Timolol) as Glaucoma first-line treatments: analysis based on the United Kingdom
R De Natale (2009)
Changes in medical and surgical treatments of glaucoma between 1997 and 2000 in France.
C. Baudouin (2003)
Treatment Carryover Impacts on Effectiveness of Intraocular Pressure Lowering Agents, Estimated by a Discrete Event Simulation Model
P. Denis (2008)
The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators.
The Agis Investigators (2000)
Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study.
I. Dielemans (1995)
Cost Effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma
Renato Natale (2009)
Detection of undiagnosed glaucoma by eye health professionals.
E. Wong (2004)
Glaucoma treatment in Australia: changing patterns of therapy 1994–2003
M. Walland (2004)
Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France.
Kenigsberg Pa (2007)
Costs and effectiveness of brimoni - dine versus brinzolamide in everyday glaucoma care : an analysis conducted on the United Kingdom General Practitioner ResearchDatabase
A Lafuma (2011)
The need and total cost of Finnish eyecare services: a simulation model for 2005–2040
A. Tuulonen (2009)
James S. Distelhorst (2003)
Costs and persistence of carbonic anhydrase inhibitor versus alpha‑2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK‑GPRD database*
A. Lafuma (2008)
Family history and risk of primary openangle glaucoma
JM Tielsch (1994)
Changes in Medical and Surgical Treatments of Glaucoma between 1997 and 2000 in France
C. Baudouin (2003)
Five-year incidence of open-angle glaucoma: the visual impairment project.
B. Mukesh (2002)
Costs and effectiveness of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma
P Denis (2008)
Economics of surgery worldwide
DR Strutton (2004)
Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
A. Lafuma (2008)
The economic impact and cost of visual impairment in Australia
H. Taylor (2006)
The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care
D. Bateman (2002)
Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study.
I. Dielemans (1996)
Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database
P. Denis (2008)
Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
J. Rouland (2005)
Modelling the lifetime economic consequences of glaucoma in France
Jean Philippe Nordmann (2009)
First-year treatment costs among new initiators of topical prostaglandin analogs
J. Schmier (2009)
Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study.
S. de Voogd (2005)
Efficiency of Glaucoma Drug Regulation in 5 European Countries: A 1995-2006 Longitudinal Prescription Analysis
R. de Natale (2011)
Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first line treatment of glaucoma: analysis
A Lafuma (2007)
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
M. Kass (2002)
Economics of Glaucoma Care
Lee Kiang (2015)
The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration
F. Ederer (2000)
Medical Predictive Factors of Glaucoma Treatment Costs
P. Denis (2004)
Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom.
G. Kobelt (1999)
First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results
J. Schmier (2010)
A review of glaucoma treatment in Scotland 1994–2004
S. Macleod (2008)
Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database
A. Lafuma (2008)
Prevalence of Primary Open-Angle Glaucoma in a Spanish Population: The Segovia Study
A. Antón (2004)
JS Distelhorst (2003)
Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies.
M. C. Leske (2007)
Incidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden: II. Results after 21 years of follow-up.
S. Åström (2007)
Family history and risk of primary open - angle glaucoma . The Baltimore Eye Sur
The Impact of a Nationwide Introduction of New Drugs and a Treatment Protocol for Glaucoma on the Number of Glaucoma Surgeries
Rikkert van der Valk (2005)
Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database*
A. Lafuma (2007)
Efficiency of glaucoma drug regulation in five European countries
R De Natale (2011)
The impact of a nation
Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries*
J. Thygesen (2008)
Clinical Outcomes of Glaucoma Treatments Over a Patient Lifetime: A Markov Model
J. P. Nordmann (2005)
Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
A. Lafuma (2011)
Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project.
Anhchuong Le (2003)
The economic burden of major adult visual disorders in the United States.
D. Rein (2006)
The rising cost of glaucoma drugs in Ireland 1996–2003
F. A. Knox (2006)
Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries
A. Lafuma (2012)
Prevalence of open-angle glaucoma in central Sweden. The Tierp Glaucoma Survey.
C. Ekström (1996)
Treatment persistence and costeffectiveness of latanoprost ⁄ latanoprosttimolol, bimatoprost ⁄ bimatoprost-timolol, and travoprost ⁄ travoprost-timolol in glau
A Lafuma (2011)
Incidence of open‐angle glaucoma in central Sweden
C. Ekström (2008)
Effect of medical therapy on glaucoma filtration surgery rates in Ontario.
R. Rachmiel (2006)
Race and primary open-angle glaucoma.
M. Martin (1985)
Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population
I Dielemans (1995)
Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population
I Dielemans (1996)
Trends in Glaucoma Surgery before and after the Introduction of New Topical Glaucoma Pharmacotherapies
D. Strutton (2004)
Cost effectiveness and cost utility of an organized screening programme for glaucoma.
Hanna Vaahtoranta-Lehtonen (2007)
This paper is referenced by
Allocating Resources for Glaucoma Care—A Review
Nkiru N. Kizor-Akaraiwe (2019)
Health Economic Analysis in Glaucoma
In-hae Park (2020)
The Current Status of Glaucoma and Glaucoma Care in Sub‐Saharan Africa
F. Kyari (2018)
Topical glaucoma therapy cost in Mexico
Gabriel S. Lazcano-Gomez (2013)
The long term effectiveness and cost‐effectiveness of initiating treatment for ocular hypertension
Aukje Gestel (2014)
Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma
P. Agrawal (2018)
A socioeconomic evaluation of early-stage and moderate glaucoma patients
Miglė Lindžiūtė (2019)
Trends in Glaucoma Medication Expenditures under Universal Health Coverage: A National Population-Based Longitudinal Survey in Taiwan
Shin-Lin Chiu (2015)
Adverse Effects, Adherence and Cost–Benefits in Glaucoma Treatment
Philippe Denis (2011)
Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review
Lester Darryl Geneviève (2019)
The Prevalence and Incidence of Glaucoma in Denmark in a Fifteen Year Period: A Nationwide Study
M. Kolko (2015)
Comparing the long-term impact on health care resources utilization and costs due to various single-piece acrylic monofocal intraocular lens implantation during cataract surgery: a cost-consequence analysis for the United Kingdom, Italy, and Denmark
Mukesh Dhariwal (2019)
Challenges of glaucoma care – high volume, high quality, low cost
A. Tuulonen (2013)